[Study on ligustrazine in reversing multidrug resistance of HepG2/ADM cell in vitro].
OBJECTIVE
To study the reverse effect of ligustrazine (TMP) on HepG2/ADM, a herd of hepatocellular carcinoma cell, multidrug resistance (MDR) and the influence of P-gp170 expression.


METHODS
The reverse effect of ligustrazine on HepG2/ADM cell was observed, with the methods of cell culture, MTT's analyze, RT-PCR and Flow cytometric, etc.


RESULTS
Ligustrazine could make MDR of cell line of HepG2/ADM reduce the expression of P-gp170, enhance the density of adriamycin in cell and increase the adriamycin's cytotoxicity. With the Flow cytometric, the results of RT-PCR showed the transcriptional activity of the MDR1 decreased.


CONCLUSIONS
Ligustrazine can reverse MDR of HCC cell line of HepG2/ADM and has prospect in clinical use.
Mei
Ying
Y
The Department of Hepato-biliary Surgery, Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China.
Shi
Yu-jun
YJ
Zuo
Guo-qing
GQ
Gong
Jian-ping
JP
Liu
Chang-an
CA
Li
Xu-hong
XH
Ren
Meng-jun
MJ
D018435:ATP Binding Cassette Transporter, Subfamily B; D002121:Calcium Channel Blockers / Q000494:pharmacology; D006528:Carcinoma, Hepatocellular / Q000378:metabolism / Q000473:pathology*; D045744:Cell Line, Tumor; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D004317:Doxorubicin / Q000378:metabolism / Q000494:pharmacology; D018432:Drug Resistance, Multiple / Q000187:drug effects*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D019450:Genes, MDR; D006023:Glycoproteins / Q000378:metabolism*; D006801:Humans; D008113:Liver Neoplasms / Q000378:metabolism / Q000473:pathology*; D011719:Pyrazines / Q000494:pharmacology*
C513055:ABCB1 protein, human; D018435:ATP Binding Cassette Transporter, Subfamily B; D002121:Calcium Channel Blockers; D006023:Glycoproteins; D011719:Pyrazines; D004317:Doxorubicin; C017953:tetramethylpyrazine